T-cells comprising anti-CD38 and anti-CD138 chimeric antigen receptors and uses thereof
US11944644B2 · kind B2 · utility
0Cited by
4References
19Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 4, 2018 |
| Grant date | Apr 2, 2024 |
| Priority date | — |
| Expiry date | Dec 14, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides T-cells expressing at least two different chimeric antigen receptors, wherein one of the CARs binds specifically to CD138 and another CAR binds specifically to CD38. In particular, the present invention provides T-cells expressing two different CARs, when one CAR comprises anti-CD138 sc Fv and the second CAR anti-CD138 sc Fv. Further, the invention provides a pharmaceutical composition comprising these dual CAR T-cells and their use in treatment of cancer, in particular multiple myeloma, and methods for preparation of these cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.